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Opinion statement
A paradigm shift towards molecular-based, personalized cancer therapeutics has
occurred in recent years and a number of targeted drugs have emerged. Various
targeted therapies like erlotinib, trastuzumab, and cetuximab have been approved in
lung, breast, and colon cancers, respectively. Numerous clinical trials involving
targeted drugs in biliary tract cancers are currently in progress, though none have
been approved for this disease. Biliary tract cancers are divided into separate
entities both anatomically and in terms of pathogenesis but are grouped together
in most trials given their rarity. Combination chemotherapy involving cisplatin and
gemcitabine is the current standard of care in the metastatic setting. In this review,
we will discuss the various molecular pathways implicated in biliary tract cancers
and potential therapeutic targets.
Classification
Biliary tract cancers (BTC) are a heterogeneous group of
cancers that are clinically and genetically divergent. BTC
can be divided anatomically into gallbladder cancers
(GBC), intrahepatic cholangiocarcinomas (IHCC), hilar
cholangiocarcinomas (HCC), and extrahepatic
cholangiocarcinomas (EHCC) [1]. HCC, also called
Klatskin’s tumors as they were first described by Gerald
Klatskin in 1965, are tumors that arise at the bifurcation
of the common hepatic duct [2]. The American Joint
Commission on Cancer (AJCC) 7th edition classified
them as different types with separate staging systems,
though the systemic management options at present
remain similar. Histologically, BTC are classified as
adenocarcinoma (90 % of cases), papillary, mucin-
ous, clear cell, signet-ring cell, adenosquamous, squa-
mous, small cell, and undifferentiated carcinomas
[3]. The exact molecular mechanisms leading to BTC
remain unknown.
Epidemiology
BTC are rare malignancies with poor prognosis, with GBC being the most
common among all BTC [4]. Population-based data from the National Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER) program esti-
mated 7865 newly diagnosed cases of GBC from 1992 to 2009 in the USA.
Incidence is higher in females, and higher incidence rates are seen in blacks and
Asians compared to whites [5]. Mortality rates are highest in Chile, India, and
Eastern Europe, suggesting geographical and racial differences [6, 7]. For IHCC
and EHCC, incidence rates in the USA are 0.88 per 100,000 and 0.72 per
100,000, respectively, based on data from the National Center for Health
Statistics [8]. The incidence of IHCC worldwide is increasing, while that of
EHCC appears to be decreasing [9, 10].
Risk factors for BTC include parasitic infections by liver flukes, gallstones,
diabetes mellitus, obesity, alcohol, inflammatory bowel disease, bile duct cysts,
smoking, and hepatitis B and C [11–15]. The presence of gallstones is by far the
most important risk factor. The exact mechanism by which gallstones cause
carcinogenesis is unknown but is probably due to persistent inflammation
leading to dysplasia and accumulation of loss of heterozygosity at various
tumor suppressor genes [16, 17]. The presence of gallbladder adenoma has also
been proposed as a risk factor [18].
Prognosis
GBC have the worst prognosis among all BTC. For resectable GBC, the median
overall survival (OS) differs somewhat depending on the actual study. A
population-based analysis using SEER data concluded that median OS for
resectable GBC is only 16 months [19]. For IHCC, OS after resection is
33 months, and the 1-, 3-, and 5-year OS estimates are 82.3, 47.1, and 32.9 %,
respectively. Another study reported OS of 18 months after R0 resection for
node-positive disease [20, 21]. Five to ten percent of patients were alive 5 years
after being diagnosed with advanced IHCC [10]. For surgically resectable HCC,
the median OS is 30 months in patients undergoing combined partial hepatic
resection and 24 months in those having bile duct resection only [22]. In
contrast, despite an increase in treatment options, locally advanced or meta-
static BTC have median OS approaching only 1 year, illustrating the need for
better therapy [23].
Chemotherapy
Treatment of early BTC is surgery, which offers potential cure. In locally
advanced HCC, neoadjuvant chemoradiation followed by liver transplan-
tation across 12 centers in the USA was shown to improve 5-year recur-
rence-free survival to 65 % [24]. Adjuvant therapy remains controversial
and no regimen has yet been accepted as a standard. Only about 10 % of
BTC are operable at the time of diagnosis. For advanced, inoperable BTC,
systemic therapy is the only option. Poor prognostic factors after resection
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include the presence of lymph node metastases, positive margins, and
poor differentiation [25, 26].
The use of chemotherapy over best supportive care was first supported in a
clinical trial comparing combination of 5-fluorouracil and etoposide vs. best
supportive care. The median OS in the chemotherapy group was 6 months,
compared to only 2.5 months in the supportive care group [27].
The current standard of care in the metastatic setting is based on the ABC-01
and ABC-02 trials from the UK [23, 28]. ABC-01, a phase II clinical trial,
demonstrated improvement in 6-month progression-free survival (PFS) favor-
ing cisplatin and gemcitabine compared to gemcitabine alone (8.0 vs.
4.0 months) [28]. ABC-02, a phase III trial, showed an improvement in OS,
with combination therapy of cisplatin and gemcitabine (11.7 months) com-
pared to gemcitabine alone (8.1 months) (hazard ratio (HR) 0.64, 95 %
confidence interval (CI) 0.52–0.80; log rank pG0.001) [23]. The Japanese BT-22
trial produced results similar to the ABC-02 trial, in which 84 patients were
randomized to either gemcitabine alone or to the combination of cisplatin and
gemcitabine [29]. A subsequent meta-analysis concluded that BTC patients
treated with gemcitabine combined with platinum agents (cisplatin or
oxaliplatin) have better outcomes compared to those not treated with this
regimen [30].
Targeted therapy
Recent studies revealed multiple clinically targetable mutations in BTC. Many
molecular pathways are implicated in carcinogenesis, and agents targeting these
pathways have shown some efficacy in BTC cell lines [31, 32]. In a recent
presentation on comprehensive genomic profiling of biliary tract cancers by
Ross et al. at the 2015 Gastrointestinal Symposium, multiple genomic alter-
ations and tumor-specific differences were noted. Next-generation sequencing
was performed on 554 BTC specimens. IHCC, EHCC, and GBC share genomic
alterations in cell cycle regulation (CDKN2B) and chromatin remodeling
(ARID1A). IHCC harbor FGFR fusions, IDH1/2 substitutions, BRAF substitu-
tions, and MET amplification with a low KRAS mutation frequency. EHCC and
GBC both have ERBB2 amplifications and PIK3CA/mTOR pathway alterations,
but KRASmutation frequencies are high in EHCC and low inGBC [33•].Whole
exome and targeted gene sequencing in earlier studies of GBC also revealed
frequent mutations in TP53, KRAS, and ERBB3 [34–36]. Microsatellite insta-
bility (MSI), which is well known in the pathogenesis of colon cancer, does not
appear to play a role in BTC [37]. Various targeted agents for BTC have been
tested in several phase I and II clinical trials (Table 1).
ErbB family signaling pathway
There are four distinct receptors that belong to the ErbB family of receptor
tyrosine kinases: epidermal growth factor receptor (EGFR, also known as ErbB-
1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3), and ErbB-4 (HER4). The intra-
cellular tyrosine kinase domain of ErbB receptors is highly conserved, while the
extracellular domains are less conserved among the four receptors, suggesting
different specificities in ligand binding. ErbB receptors are important in the
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development of different organs, and the interaction of ErbB receptors and their
ligands are associated with tumorigenesis [38]. EGFR and HER2 inhibitors
tested in BTC cell lines in combination with gemcitabine have shown promis-
ing activity [31], and they are being investigated in clinical trials, either alone or
in combination with chemotherapy (Table 2).
EGFR pathway
EGFR is commonly expressed in BTC and is found in 100% of IHCC, 52.6% of
EHCC, and 38.5 % of GBC in one study [31]. A Japanese cohort study dem-
onstrated that EGFR expression in IHCC is significantly associated with poor
prognosis, while its presence in EHCC may represent tumor progression and
invasion [39]. Because EGFR antibodies and inhibitors have been proven
clinically to be efficacious for many cancers, they have also been investigated in
BTC.
Erlotinib
Erlotinib is an orally active, potent, selective, and reversible inhibitor of
EGFR. Its use in various cancers, such as lung, head, and neck cancers, are
well documented. EGFR overexpression is seen in several BTC studies and
has been studied as a therapeutic target [40, 41]. Several phase II trials
have investigated the role of erlotinib in the management of advanced
BTC. Philip et al. evaluated 42 patients with advanced BTC and showed
median PFS of 2.6 months and median OS of 7.5 months. However, more
Table 2. Ongoing clinical trials incorporating targeted agents
Drug Class Phase Arms NCT number
Cetuximab EGFR antibody II Gemcitabine + oxaliplatin with or without cetuximab NCT01267344
Afatinib EGFR inhibitor I Cisplatin + gemcitabine + afatinib (single arm) NCT01679405
Cediranib VEGF inhibitor II FOLFOX with cediranib (single arm) NCT01229111
Regorafenib Multikinase inhibitor II Regorafenib (single arm) NCT02053376
Regorafenib Multikinase inhibitor I/II Gemcitabine + oxaliplatin + regorafenib (single arm) NCT02386397
Regorafenib Multikinase inhibitor II Regorafenib (single arm) NCT02053376
Regorafenib Multikinase inhibitor II Regorafenib (single arm) NCT02115542
Ponatinib Multikinase inhibitor II Ponatinib (single arm) NCT02265341
Pazopanib Multikinase inhibitor II Pazopanib (single arm) NCT01855724
Pazopanib Multikinase inhibitor II Pazopanib + gemcitabine (single arm) NCT01855724
Trametinib MEK inhibitor II Trametinib vs. 5-FU NCT02042443
Trametinib MEK inhibitor II Trametinib (single arm) NCT01943864
Selumitinib MEK inhibitor II Cisplatin + gemcitabine with or without selumitinib NCT02151084
Binimetinib MEK inhibitor I/II Cisplatin + gemcitabine + binimetinib (single arm) NCT01828034
Vismodegib Hh pathway inhibitor I Vismodegib (single arm) NCT00968981
RO4929097 Notch inhibitor I RO4929097 (single arm) NCT01096355
BGJ 398 FGFR inhibitor II BGJ 398 (single arm) NCT02150967
Ponatinib FGFR inhibitor II Ponatinib (single arm) NCT02265341
AG-881 IDH inhibitor I AG 881 (single arm) NCT02481154
AG-120 IDH inhibitor I AG-120 (single arm) NCT02073994
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than 50 % of these patients received prior therapy; thus, these patients
might have worse characteristics compared to average. In addition, 7
(17 %) patients were progression free at 24 weeks and all were EGFR/
HER1 positive, but the correlation between response and EGFR/HER1
status could not be measured accurately given the small sample size [42].
Lubner et al. investigated erlotinib in combination with bevacizumab, a
vascular endothelial growth factor (VEGF) inhibitor. Nine patients (18 %)
achieved an at best response of partial response (PR), 6 (12 %) of which
had responses confirmed 4 weeks after their initial responses were ob-
served. Median OS was 9.9 months, similar to that of historical controls
[43].
In an open-label, randomized phase III study, Lee et al. assessed the
efficacy of the addition of erlotinib to gemcitabine and oxaliplatin as first-
line therapy for metastatic BTC. Two hundred sixty-eight South Korean
patients were assigned in a 1:1 ratio to receive gemcitabine and oxaliplatin
with or without erlotinib. Median PFS was 5.8 months in the chemother-
apy plus erlotinib group and 4.2 months in the chemotherapy alone group
(HR 0.80, 95 % CI 0.61–1.03, p=0.087). OS was the same (9.5 months)
for both groups (HR 0.93, 95 % CI 0.69–1.25, p=0.611). Subgroup anal-
ysis of PFS in cholangiocarcinoma (HR 0.73) and GBC/ampulla of Vater
(HR 0.99) cancers showed that much of the improvement in PFS came in
the cholangiocarcinoma subgroup. This trial is the first phase III trial to
assess a targeted therapy plus chemotherapy combination for patients with
advanced BTC. However, the addition of erlotinib did not produce a
significant improvement in median PFS. The study was flawed as it was
not adequately powered and had a small sample size. The study was also
limited to patients from South Korea and might not be generalizable to the
non-Asian population [44••].
Cetuximab
Cetuximab, an anti-EGFR antibody, is evaluated in combination with
gemcitabine/oxaliplatin chemotherapy in BTC in several phase II trials. An
earlier study showed encouraging results in locally advanced or metastatic BTC
patients who received gemcitabine/oxaliplatin plus cetuximab. Of the 30 en-
rolled patients, 10 % patients achieved CR, while 53 % achieved PR. Nine
patients underwent potentially curative secondary resection after major re-
sponse to therapy [45]. However, subsequent studies failed to demonstrate a
similar benefit. Malka et al. recruited 150 patients with locally advanced or
metastatic BTC, who were randomized to receive gemcitabine/oxaliplatin with
or without cetuximab in the first-line setting. Median PFS was 6.1 months
(95 % CI 5.1–7.6) with cetuximab and 5.5 months (95 % CI 3.7–6.6) without
cetuximab, while median OS was 11.0 months (95 % CI 9.1–13.7) with
cetuximab and 12.4 months (95 % CI 8.6–16.0) without cetuximab. Despite
being well tolerated, the addition of cetuximab to gemcitabine and oxaliplatin
did not improve outcomes when used as first-line treatment for patients with
advanced BTC [46•]. Chen et al. investigated whether KRAS mutation status
influences response to cetuximab. One hundred twenty-two patients were
randomized to receive gemcitabine/oxaliplatin with or without cetuximab.
Median PFS was 6.7 months with cetuximab and 4.1 months without
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cetuximab (p=0.05), while median OS was 10.6 months with cetuximab and
9.8 months without cetuximab (p=0.91). KRAS mutations, detected in 36 % of
tumors, did not affect the objective response rate (ORR) or PFS [47•].
Cetuximab was also evaluated in combination with gemcitabine and capecita-
bine in the first-line setting, but ORR was only 17.6 %, with a median PFS of
32.3 weeks and OS of 62.8 weeks [48].
Panitumumab
Panitumumab is a fully humanized anti-EGFR antibody. Given its role in KRAS
wild-type colorectal cancers, it has also been studied in the first-line setting in
advanced BTC phase II trials. Hezel et al. evaluated gemcitabine and oxaliplatin
in combination with panitumumab in KRAS wild-type metastatic BTC. ORR
was 45 %, median PFS was 10.6 months, and median OS was 20.3 months
[49]. An Italian group recently presented preliminary data in a phase II ran-
domized, open-label trial, in which 89 patients with KRAS wild-type metastatic
or unresectable BTC were randomized to receive gemcitabine and oxaliplatin
with or without panitumumab. No statistical significance for median PFS and
OS was noted between the two arms, though there was a trend toward im-
provedORR and PFS in the armwith panitumumab [50]. Jensen et al. looked at
the regimen gemcitabine, oxaliplatin, and capecitabine in combination with
panitumumab in KRASwild-type advanced BTC.ORRwas 33% and the disease
control rate was 86 %. Median PFS was 8.3 months and median OS was
10.0 months. The treatment was overall tolerable with some EGFR-related skin
adverse events [51]. Sohal et al. reported data involving yet a different regimen,
gemcitabine and irinotecan in combination with panitumumab. A promising
ORR of 69 % was noted, though median PFS of 9.7 months and OS of
12.9 months were relatively similar to previous trials [52]. However, given that
these phase II trials had small sample sizes, the role of panitumumab in biliary
tract cancers remains to be defined.
HER2 pathway
HER2 belongs to the ErbB family of receptor tyrosine kinases. It is overexpressed
in about 10 % of GBC and 26.3 % EHCC in one study [31]. HER2 was first
studied in breast carcinoma, and its overexpression in human breast carcinomas
is associated with a more aggressive course of disease [53]. In an experimental
tumor model, overexpression of HER2 in the basal layer of the biliary tract
epithelium resulted in GBC in 100% of transgenicmice by 3months of age and
in other BTC at a 30 % incidence rate [54]. Agents targeting HER2 are being
tested in BTC patients given its efficacy in other cancers, though none clinically
proven to improve outcomes thus far.
Trastuzumab
Trastuzumab is a monoclonal antibody that targets the HER2 receptor and
is mainly used in the treatment of HER2-positive breast cancers and HER2-
positive cancers involving the gastroesophageal junction. However, its role
in BTC is not well defined. In a retrospective analysis, Javle et al. evaluated
BTC patients with HER2 genetic aberrations or protein overexpression who
received HER2-directed therapy in combination with concurrent therapy of
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physician’s choice. Of the eight GBC patients who received trastuzumab,
CR was seen in one patient, while there were five patients with PR, one
with mixed response, and one with stable disease. All five cholangiocarci-
noma patients had disease progression while on trastuzumab as part of its
treatment [55].
Lapatinib
Lapatinib is an orally administered, dual tyrosine kinase inhibitor against EGFR
and HER2. It was tested in a phase II study in patients with advanced BTC but
found to have no response. Median PFS was 1.8 months and median OS was
5.2 months [56].
VEGF pathway
VEGF facilitates tumorigenesis in a variety of tumors, including BTC. Its
function is not just limited to angiogenesis and vascular permeability, but
also mediates signaling in tumor cells [57]. It is highly expressed in BTC,
but expression varies according to the tumor type. In one study, 75 % of
GBC express VEGF. VEGF appears to be correlated with more advanced
and metastatic stages, and its expression is associated with poor prognosis
[58].
Bevacizumab
Bevacizumab is a recombinant humanized monoclonal antibody directed
against VEGF. It has activity in various solid tumors in the metastatic setting,
including colorectal, lung, breast, renal, and ovarian. In addition to the
bevacizumab plus erlotinib trial described by Lubner et al. [43], bevacizumab’s
role in BTC has been investigated in phase II studies in combination with other
agents. Zhu et al. enrolled 35 patients whowere given bevacizumab followed by
gemcitabine and oxaliplatin. Median PFS was 7.0 months. FDG-PET scans
demonstrated a significant decrease in maximum standardized uptake value
(SUV (max)) after only 2 cycles of treatment [59]. Iyer et al. investigated yet
another regimen and recently presented data looking at gemcitabine, capecita-
bine, and bevacizumab in patients with advanced BTC in the first-line setting.
Median PFS of 8.1 months and OS of 11.3 months were similar to standard
therapy [60].
Cediranib
Cediranib is a potent inhibitor of the VEGF receptor tyrosine kinases and also
with some activity against platelet-derived growth factor (PDGF) receptors and
c-Kit [61]. Given that VEGF is overexpressed in BTC and VEGFR1 and VEGFR2
are overexpressed in adjacent endothelial cells, cediranib has also been inves-
tigated in a recent phase II study [58, 62]. Subjects were randomized to receive
cisplatin and gemcitabine plus either cediranib or placebo. No statistically
significant difference in median PFS was observed: 7.7 months (95 % CI 6.3–
9.3) in the cediranib arm vs. 7.4 months (95 % CI 5.7–8.6) in the placebo arm.
There was a trend towards longer OS in the cediranib arm (14.1 months, 95 %
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CI 10.2–16.0) compared to the placebo arm (11.9 months, 95 % CI 9.2–13.4).
However, it did appear to improve the ORR in this trial: 43 % in the cediranib
arm compared to 19 % in the placebo arm [63•]. A phase II trial investigating
cediranib in combination with modified FOLFOX6 in advanced BTC is now
underway [64].
Sorafenib
Sorafenib is an oral multikinase inhibitor that inhibits cell surface tyrosine
kinase receptors, including VEGF receptors and PDGF receptor-β, and blocks
downstream intracellular serine/threonine kinases, such as Raf-1, wild-type,
andmutant B-Raf, involved in tumor cell proliferation and angiogenesis [65]. It
has been shown to be effective in hepatocellular carcinoma and renal cell
carcinoma, but the same has not been demonstrated in advanced BTC. In one
study, ORR was only 2 %, median PFS was 2.3 months, and median OS was
4.4 months [66]. Another trial involving sorafenib was terminated early given
that it failed tomeet the primary objective or response probability. No objective
responses were observed. Median PFS was 3 months and median OS was
9 months [67].
Other trials have evaluated sorafenib in combination with standard
chemotherapy. Moehler et al. investigated gemcitabine with either sorafe-
nib or placebo in the first-line setting. However, longer median PFS and
OS were actually seen in the gemcitabine plus placebo arm [68]. A ran-
domized, double-blinded, multicenter phase II trial by Krege et al. com-
paring a combination of gemcitabine, cisplatin with either sorafenib or
placebo found no significant difference in PFS and OS between the two
arms [69]. Finally, Lee et al. compared cisplatin, gemcitabine, and sorafe-
nib to historical data and showed no improvement in efficacy, but there
was an increase in toxicity [70].
Sunitinib
Sunitinib is another oral small molecule inhibitor that targets multiple
intracellular and receptor protein kinases, including VEGF and PDGF
receptors, c-Kit, and rearranged during transfection (RET). It is approved
for gastrointestinal stromal tumor and renal cell carcinoma [71]. In a
recent phase II study, Yi et al. investigated the role of sunitinib as a second-
line treatment in advanced BTC. Only marginal efficacy was demonstrated.
ORR was 8.9 % and median PFS was 1.7 months [72].
Vandetanib
Vandetanib is an oral multikinase inhibitor that targets VEGF, EGFR, as well as
the RET kinase. Its role in the treatment of thyroid cancer has been well
documented. In an Italian (VanGogh) study, 165 BTC patients who had not
received any prior chemotherapy were randomized into three groups: vandet-
anib monotherapy (V), vandetanib plus gemcitabine (V/G), and gemcitabine
plus placebo (G/P). Median PFS was 105 days (95 % CI 72–155), 114 days
(95 % CI 91–193), and 148 days (95 % CI 71–225), while median OS was
228 days (95 % CI 190–364), 284 days (95 % CI 213–359), and 307 days
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(95 % CI 254–523) for V, V/G, and G/P, respectively. This study did not
demonstrate any superiority of vandetanib alone or in association with
gemcitabine when compared with gemcitabine alone [73•].
MEK pathway
In addition to targeting growth factor receptors, recent research has also focused
on interfering with various signaling pathways essential to the regulation of
cellular processes. These include the RAS/RAF/mitogen-activated protein kinase
kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway,
which is activated by a diverse group of extracellular signals, such as growth
factor receptors and cytokines. Activated RAS starts a phosphorylation cascade
involving RAF kinase, MEK1/MEK2, and ERK1/ERK2 [74]. Phosphorylated
ERKs form homodimers and translocate to the nucleus to perform important
cellular functions [75]. In preclinical studies, CI-1040, a MEK inhibitor, has
been investigated in a panel of human cancer cell lines and showed broad
activity, particularly in cell lines harboring the BRAF mutation [76]. One study
reported that BRAF mutations were identified in 22 % of cholangiocarcinoma,
suggesting the potential role ofMEK inhibitors in themanagement of BTC [77].
Selumetinib is a second-generation, potent, uncompetitive inhibitor of
MEK1/2. It was investigated in a phase II study for patients with advanced
BTC. Median PFS was 3.7 months and OS was 9.8 months. The absence of
phosphorylated ERK staining was associated with a lack of response [78].
Binimetinib, another potent, uncompetitive inhibitor of MEK1/2, was investi-
gated in phase I trials both alone and in combination with standard chemo-
therapy, with encouraging activity and tolerable safety profile [79, 80]. Phase II
studies exploring this drug in BTC are ongoing (NCT02151084,
NCT01828034).
PIK3CA/PTEN/AKT/mTOR pathway
The phosphatidylinositol 3-kinase (PIK3CA)/phosphatase and tensin homologue
(PTEN)/AKT/mammalian target of rapamycin (mTOR) pathway is important for
cell growth and survival. Abnormal activation and genetic mutations in this
pathway predispose to the development ofmany cancers, and hence, this pathway
has gained importance in recent years as a target for drug development. A study
revealed that 12.5 % of patients with GBC have activating mutations in PIK3CA
[81]. Deregulation of this pathway has been shown to induce GBC in normal
gallbladder epithelial cells [82]. Buparlisib (BKM120), a PI3K inhibitor, is being
tested in various phases of clinical trials in several malignancies either as a single
agent or combined with other targeted agents or conventional chemotherapy.
mTOR is upregulated in many cancer types and is currently indicated for the
treatment of advanced breast cancer, neuroendocrine tumors of pancreatic
origin, and renal cell carcinoma [83]. In a phase II Italian study, 39 patients with
locally advanced, metastatic, or recurrent BTC progressing despite previous
chemotherapy received everolimus, an inhibitor of mTOR. ORR was only
5.1 %, median PFS was 3.2 months, and median OS was 7.7 months [84]. In a
phase II Australian study, everolimuswas administered in the first-line setting in
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advanced BTC. Preliminary results were recently presented, with ORR 12 %,
median PFS 6.0 months, and median OS 9.5 months [85]. Larger studies are
necessary to clarify the efficacy of mTOR inhibitors in the treatment of BTC.
Heat shock protein (HSP90) is a chaperone protein that helps maintain
structural integrity and function of specific protein targets involved in cell cycle.
It has antiapoptotic activity and can target multiple pathways with promising
role in many malignancies. The combination of HSP90 inhibitor and PI3K/
mTOR inhibitor was synergistic, inducing cell death in preclinical models of
cholangiocarcinoma [86].
Hedgehog pathway
The Hedgehog signaling pathway is involved in numerous developmental
processes including cell patterning, cell fate, proliferation, survival, and differ-
entiation during early development [87]. This pathway is dormant in most
adult tissues, but its activation has been implicated in carcinogenesis. The
components of the Hedgehog pathway include three secreted ligands (Sonic
Hh, Indian Hh, and Desert Hh), a negative regulatory receptor (Patched
[PTCH]), a positive regulatory receptor (smoothened [SMO]), and glioma-
associated oncogene transcription factors. Nevoid basal cell carcinoma syn-
drome consisting of multiple basal cell carcinomas is associated with germline
loss of function of mutation in PTCH. PTCH 1 and 2 mutations are also found
in 30 % of sporadic basal cell carcinomas [88]. Vismodegib, a small molecule
that inhibits the Hedgehog pathway, is approved in basal cell carcinoma and is
being studied in phase I and II trials in solid tumors [89]. Blockage of the
Hedgehog pathway has been shown to decrease survival and proliferation of
cancer cells in cholangiocarcinoma cell lines [90].
Notch pathway
The Notch pathway is another attractive target in cancer therapy. It is essential
for tumor angiogenesis and is needed to establish and maintain stem cell
population. It has an established role in hematologic malignancies [91]. Notch
signaling can be oncogenic or tumor suppressive depending on the cellular
context. Mammals have four notch receptors (1–4) and five ligands. Alteration
of Notch pathways in solid and liquid tumors can lead to oncogenesis [92].
A study revealed that aberrant expression of Notch receptors 1 and 3 may
play a role in the cancer progression of BTC [93]. RO-4929097 (a notch
signaling inhibitor) is being tested in various phase I and II trials in solid tumors
(Table 2). Further research is needed to determine if this pathway can be used as
a potential target in BTC.
Immunotherapy
Tumors suppress the immune system in the tumor microenvironment and also
systemically. The immune system responds to cancer by reacting against tumor-
specific or tumor-associated antigens (TAA). Major developments in immuno-
logical techniques have helped us discover that the immune system does
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recognize cancer antigens. Many TAA used in cancer therapeutics have been
developed in recent years. Passive immunity is using monoclonal antibodies
against tumor antigens or infusion of tumor-specific autologous T cells.
Induction of active immunity by vaccination, which boosts tumor-specific
antibodies and T cells, is being studied [94].
MUC1 is a large membrane glycoprotein that is identified as a tumor
antigen. The MUC1 peptide vaccine has been evaluated in pancreatic and BTC
in two separate trials. Yamamoto et al. evaluated eight eligible patients with
metastatic disease. Seven had progressive disease and one had stable disease
with a tendency for increased circulating anti-MUC1 IgG antibody after vacci-
nation [95]. Lepisto et al. conducted a phase I/II trial using MUC1 peptide-
loaded dentritic cells (DC) vaccine in the adjuvant setting in BTC or pancreatic
cancer. The vaccine was well tolerated with no significant toxicities. Twelve
patients were enrolled and four of them were alive at 4 years [96].
Subsequently, Shimizu et al. conducted a phase I trial on 36 patients with
IHCC after resection. Patients were vaccinated with autologous tumor lysate
pulsed DC plus ex vivo activated T-cell transfer. Median PFS and OS were 18.3
and 31.9 months in patients receiving adjuvant immunotherapy and 7.7 and
17.4 months in the group receiving surgery alone (p=0.005 and 0.022, respec-
tively) [97]. Further randomized controlled trials are needed to study the effects
of immunotherapy in BTC.
Others
The fibroblast growth factor receptor (FGFR) pathway is involved in cellular
migration, proliferation, survival, and differentiation. Various mutational pro-
filing studies in cholangiocarcinoma have detected genetic alterations in the
FGFR pathway, exclusively in IHCC, and are shown to be associated with a
more indolent course [98, 99]. FGFR2 fusions occur in 13.6 % of IHCC [100].
BGJ 398, an oral FGFR inhibitor, is being evaluated in a phase II trial in patients
with FGFR2 gene fusion/translocation [101]. A number of other clinical trials
involving FGFR small molecule inhibitors in BTC are in progress (Table 2).
Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of
isocitrate to α-ketoglutarate (α-KG). α-KG, a substrate for multiple enzymes, is
important for cellular response to oxidative stress. IDHmutation results in
accumulation of D-2-hydroxyglutarate, predisposing cells to malignant trans-
formation. These mutations are commonly found in gliomas and acute mye-
loid leukemias. A study reported IDH 1 and 2 mutations in IHCC (9 of 40,
23%), but none in EHCC and GBC cases [102•]. The effect of IDH inhibitors is
currently being evaluated in clinical trials involving solid tumors such as
cholangiocarcinoma that harbor these mutations [103, 104].
Ribonucleotide reductase is an enzyme involved in DNA synthesis. 3-
Aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP), a new, potent,
small molecule inhibitor of ribonucleotide reductase was tested in combination
with gemcitabine in BTC.ORRwas seen in 3 of the 23 tested patients (13%) [105].
GBC are twice more common in females and expression of estrogen recep-
tors in GBC has been shown. Targeting estrogen receptors could have some role
in the treatment, though the exact mechanism of how these receptors promote
GBC is unknown [106].
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Conclusion
BTC are rare malignancies in western countries but very prevalent in
northern India and Chile. GBC, the most aggressive cancer among all, is
categorized as an orphan disease. Despite recent advances in our knowl-
edge on the pathogenesis of BTC at the molecular level, prognosis remains
poor. The Cancer Genome Atlas (TCGA) helps identify genomic changes in
specific tumor types and develop an integrated picture of commonalities
and differences across tumor lineages [107]. BTC are currently being in-
vestigated in TCGA. Understanding the genomic alterations may help us
better understand the pathogenesis and identify targetable mutations.
Finally, the difficulty in the classification, molecular heterogeneity, and
rarity of this disease makes clinical trials more challenging. Detection of
tumors at earlier stages and improvement in surgical techniques are
needed, but advancement of systemic treatment is also necessary. Targeted
drugs against ErbB, VEGF, PI3K/AKT, MEK/ERK, Hedgehog, and Notch
pathways are being investigated in BTC (Table 2). Enrollment of patients
in clinical trials and close collaboration among international cancer orga-
nizations may lead to better outcomes in this aggressive disease.
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